Skip to main content
SpringerLink
Log in

Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Zeng C, Yu X, Lai J, Yang L, Chen S, Li Y (2015) Overexpression of the long non-coding RNA PVT1 is correlated with leukemic cell proliferation in acute promyelocytic leukemia. J Hematol Oncol 8:126

    Article  PubMed  PubMed Central  Google Scholar 

  2. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S et al (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369:111–121

    Article  CAS  PubMed  Google Scholar 

  3. Zhu HH, Qin YZ, Huang XJ (2014) Resistance to arsenic therapy in acute promyelocytic leukemia. N Engl J Med 370:1864–1866

    Article  CAS  PubMed  Google Scholar 

  4. Lou Y, Ma Y, Sun J, Ye X, Pan H, Wang Y et al (2015) Evaluating frequency of PML-RARA mutations and conferring resistance to arsenic trioxide-based therapy in relapsed acute promyelocytic leukemia patients. Ann Hematol 94:1829–1837

    Article  CAS  PubMed  Google Scholar 

  5. Zhu HH, Wu DP, Jin J, Li JY, Ma J, Wang JX et al (2013) Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 31:4215–4221

    Article  CAS  PubMed  Google Scholar 

  6. Lallemand-Breitenbach V, Jeanne M, Benhenda S, Nasr R, Lei M, Peres L et al (2008) Arsenic degrades PML or PML-RARalpha through a SUMO-triggered RNF4/ubiquitin-mediated pathway. Nat Cell Biol 10:547–555

    Article  CAS  PubMed  Google Scholar 

  7. Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S et al (2010) PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 18:88–98

    Article  CAS  PubMed  Google Scholar 

  8. O'Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA et al (2013) Acute myeloid leukemia, version 2.2013. J Natl Compr Cancer Netw 11:1047–1055

    Article  Google Scholar 

  9. Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R et al (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119:1599–1606

    Article  CAS  PubMed  Google Scholar 

  10. Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J et al (2005) Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol 23:4110–4116

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The research was supported by National Natural Science Foundation of China (No. 81402074, 81400167, 81670142 ); Natural Science Foundation of Jiangsu province (No. BK20140224, BK20140227); China Postdoctoral Science Foundation funded project (No. 2015M570481, 2015M571820, 2016T90506, 2016T90509); Jiangsu Qing Lan Project for Mingshan Niu; The Project of Invigorating Health Care through Science, Technology and Education (Jiangsu Provincial Key Medical Discipline).

Author information

Author notes

  1. Mingshan Niu and Yangling Shen contributed equally to this work.

Authors and Affiliations

  1. Blood Diseases Institute, Jiangsu Key Laboratory of Bone Marrow Stem Cell, Xuzhou Medical University, Xuzhou, Jiangsu, China

    Mingshan Niu, Yangling Shen, Jialei Qi, Qingyun Wu, Yao Yao & Kailin Xu

  2. Department of Hematology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China

    Mingshan Niu, Wei Sang, Jiang Cao, Wei Chen & Kailin Xu

  3. Insititute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, Jiangsu, China

    Xuejiao Liu

Authors
  1. Mingshan Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yangling Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jialei Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuejiao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Sang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qingyun Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jiang Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yao Yao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Kailin Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yao Yao or Kailin Xu.

Ethics declarations

Conflict of interest

The authors declare no conflict of interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niu, M., Shen, Y., Qi, J. et al. Effects of realgar (As4S4) on degradation of PML-RARA harboring acquired arsenic-resistance mutations. Ann Hematol 96, 1945–1948 (2017). https://doi.org/10.1007/s00277-017-3093-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-017-3093-8

Search

Navigation